1. Edoxaban (LIXIANA®) in the treatment of venous thromboembolism
- Author
-
Antonello D'Andrea, Andreina Carbone, Gerardo Nigro, Anna Rago, Paolo Golino, Andrea Antonio Papa, Biagio Liccardo, Vincenzo Russo, Carmen Spaccarotella, Roberta Bottino, Bottino, Roberta, Carbone, Andreina, Liccardo, Biagio, D'Andrea, Antonello, Rago, Anna, Papa, Andrea Antonio, Spaccarotella, Carmen, Golino, Paolo, Nigro, Gerardo, Russo, Vincenzo, Bottino, R., Carbone, A., Liccardo, B., D'Andrea, A., Rago, A., Papa, A. A., Spaccarotella, C., Golino, P., Nigro, G., and Russo, V.
- Subjects
vitamin K antagonist ,medicine.medical_specialty ,pulmonary embolism ,medicine.drug_class ,Pyridine ,venous thromboembolism ,Population ,direct oral anticoagulant ,030204 cardiovascular system & hematology ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Randomized controlled trial ,Edoxaban ,law ,cancer ,Medicine ,cardiovascular diseases ,Intensive care medicine ,education ,deep venous thrombosi ,oral anticoagulation ,education.field_of_study ,business.industry ,Cancer ,Vitamin K antagonist ,medicine.disease ,Pulmonary embolism ,Safety profile ,chemistry ,030220 oncology & carcinogenesis ,edoxaban ,Molecular Medicine ,Thiazole ,Cardiology and Cardiovascular Medicine ,business ,Venous thromboembolism ,Factor Xa Inhibitor ,Human - Abstract
Standard therapy for venous thromboembolism (VTE) includes the use of heparins and vitamin K antagonists. Randomized clinical trials have shown that non-vitamin K oral anticoagulants are as effective and safe as standard therapy in VTE treatment, with an improved pharmacological profile. Edoxaban, a direct inhibitor of factor Xa, has demonstrated noninferiority to standard therapy for the treatment of VTE, preserving a high safety profile even in long-term therapy, in frail patients and in severe clinical presentations. The present paper focuses on the role of edoxaban in VTE treatment, from general population to cancer patients, presenting the available data from randomized clinical trials and real world, to discuss edoxaban use in clinical practice.Lay abstractAnticoagulants are the main treatment for venous thromboembolism (VTE), a condition in which a blood clot forms in the deep veins of the body, in areas such as the leg. Currently, direct oral anticoagulants are available as an alternative to warfarin, a drug that is sensitive to changes in the diet and requires constant monitoring. Direct-oral anticoagulants have been shown in large-scale studies to be as effective and safe as warfarin in the treatment of this disease, with the advantage of not being affected by the food the patient eats. Among these, edoxaban only needs to be taken once a day and has obtained many favorable results in high-risk populations (such as the elderly, patients with cancer, those receiving prolonged treatment or those with severe VTE). In this review we discuss the role of edoxaban for the treatment of VTE in several scenarios and review its role in clinical practice.Tweetable abstractEdoxaban is effective and safe for the treatment of venous thromboembolism (VTE) even in special population. Caution is needed in some patients to avoid major bleeding events. Favorable results are also shown in the ETNA VTE study, a real-world data prospective registry. #edoxaban #VTE #efficacy #safety
- Published
- 2021